Kevin Doyle

Kevin Doyle is currently the Vice President of Medicinal Chemistry & DMPK at Cancer Research Horizons. Kevin has a strong background in pharmaceutical research and has held leadership positions at companies such as Cerevance, GW Pharmaceuticals plc, and Domainex. Kevin holds a PhD in Chemistry from Loughborough University and has completed post-doctoral studies at the University of Nottingham and University of Florida.